Wire · opportunities
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The FDA granted accelerated approval to neladalkib for previously treated ALK-positive locally advanced or metastatic non-small cell lung cancer, supported by phase 1/2 ALKOVE-1 trial data showing meaningful overall response rates and durable responses in heavily pretreated patients.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You have a new option to pitch for ALK-positive lung cancer after multiple prior therapies. This approval opens a door to users who failed existing ALK drugs, so tailor your clinical or commercial approach accordingly.
◆ Coverage
3 sources · 17 Nov 2026
◆ Related on Wire
◆ Topics